GB Sciences’ First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson’s Disease Has Been Issued in China
LAS VEGAS, March 20, 2023 (Newswire.com) - Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, has recently been issued a patent in China to protect its proprietary cannabinoid-containing formulation for the treatment of Parkinson's disease. China is an increasingly important pharmaceutical market with cultural acceptance of plant-based formulations, which is a good fit for Gb Sciences' drug candidates. Gb Sciences' first international patent also confirms that the Company's intellectual property strategy can work globally and strengthens the Company's patent portfolio. The global market for treatments of Parkinson's disease is projected to grow to $8.8 billion by the year 2026, and new therapies to address Parkinson's disease symptoms are greatly needed.
"The issuance of Gb Sciences' first international patent protecting methods of using our proprietary cannabinoid-containing formulations for treating Parkinson's disease is an important milestone in the development of these vitally important therapies. Gb Sciences' recent patent issued in China validates both our plant-inspired drug discovery process and intellectual property strategy, which involve defining and protecting Minimum Essential Mixtures," explained Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences, Inc. "Gb Sciences starts its drug discovery process with plant-based therapies that are working anecdotally or in traditional medical systems, then we systematically reduce the number of compounds to reveal Minimum Essential Mixtures. Gb Sciences' novel Minimum Essential Mixtures retain the increased efficacy of whole plant medicines, but they are easier to manufacture with precision at scale like single ingredient drugs. These Minimum Essential Mixtures are a viable alternative to standard single ingredient drugs or traditional whole plant medicines."
Gb Sciences' Minimum Essential Mixture-based drug development strategy does not aim to treat complex diseases as if they were caused by a single factor, but instead addresses the combination of factors that lead to a complex human disorder. Minimum Essential Mixtures (MEMs) are potentially more effective than single ingredient drugs because the different active ingredients target the multiple human processes responsible for complex diseases, such as neurodegeneration, heart disease, and cancers. As such, MEMs may offer a more holistic treatment for complex disorders such as Parkinson's disease that cannot be attributed to a single cause, while maintaining the manufacturing and quality control advantages of single ingredient drugs.
Gb Sciences' patent portfolio currently contains six issued U.S. and four issued foreign patents, as well as 15 U.S. and 49 foreign patent-pending applications that cover our novel AI-enabled drug discovery platform and proprietary plant-inspired therapies for more than 65 different disorders.
To learn more about Gb Sciences, visit www.gbsciences.com.
About Gb Sciences and GbS Global Biopharma
Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The 'plant-inspired' active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and four issued foreign patents, as well as 15 U.S. and 49 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada (NRC). The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Contact Information:Alexis Quintal
[email protected]
Original Source: GB Sciences' First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease Has Been Issued in China
Grand Opening of One of the World’s Largest Anime Shops, animate Ikebukuro Flagship Store, on March 16, 2023, in Tokyo, Japan
TOKYO, March 17, 2023 (Newswire.com) - On March 16, 2023, the newly renovated animate Ikebukuro Flagship Store, known for its anime, manga, and game merchandise, will be holding its grand opening in Ikebukuro, Tokyo, Japan. animate is an anime merchandise specialty store with 122 stores in Japan and 11 stores overseas (Shanghai, Bangkok, Seoul, Taipei, and other major cities).
In addition to offering popular anime character merchandise, manga, CDs, DVDs/Blu-rays, and games, there will be a newly opened "animate Theater" for visitors to experience the world of anime and comics through events, stage performances, live script readings, and talk shows; as well as "Space Galleria", where anime and game content will be exhibited, and exclusive items sold. The new store will offer anime merchandise and events from the second underground floor all the way up to the ninth floor for visitors to enjoy.
New area information
animate Theater
animate Theater is a new multi-purpose theater located in the basement of the animate Ikebukuro Flagship Store. It features a maximum seating capacity of 208 and will host various shows such as stage performances, talk shows, and live script readings.
Space Galleria
Space Galleria, a new venue dedicated to hosting exhibitions, has been added to the eighth floor of the animate Ikebukuro Flagship Store. This will be a space to showcase content from various genres such as anime, manga, and more.
animate cafe Gratte Ikebukuro Flagship Store
Visitors can enjoy a graphic latte (Gratte) with anime artwork printed on the cream topping and icing cookies.
*Entry to certain areas requires a ticket purchase.
Grand opening plan
Latest information 1
In conjunction with the grand opening, animate will hold a congratulatory shikishi board exhibition, comment video broadcast, and more.
■Grand Opening Commemorative Celebration Shikishi Display
Date: March 13 - April 16, 2023
Location: animate Ikebukuro Flagship Store
Contents: In celebration of the grand opening, about 350 autographed shikishi boards from celebrities will be displayed in-store.
■Grand Opening Celebration Video Broadcast
Date: March 16 - April 20, 2023 (planned)
Location: animate Ikebukuro Flagship Store
Contents: In celebration of the grand opening, a video of congratulatory comments will be broadcast on the in-store monitor.
Latest information 2
A life-size figma of Meito Anizawa will be on display at the animate Ikebukuro Flagship Store
To celebrate the grand opening, a life-size figma (figure) of animate's promotional character, "ANIME TENCHOU," will be brought back for a limited time.
Date: From March 2023
Location: animate Ikebukuro Flagship Store 1F
[Opening] March 16, 2023
[Location] 1-20-7 East Ikebukuro, Toshima, Tokyo 170-0013
■URL
animate Ikebukuro Flagship Store Special Site: https://www.animate.co.jp/ex/ikebukuro2023/
About animate
One of the largest anime goods store chain in Japan, animate specializes in anime, manga, and game merchandise; with over 120 shops across all 47 prefectures and 11 stores overseas.
https://www.animate.co.jp/en/
Yumiko Yamashita
Public Relations
[email protected]
03-3972-3355
Related Images
Original Source: Grand Opening of One of the World's Largest Anime Shops, animate Ikebukuro Flagship Store, on March 16, 2023, in Tokyo, Japan
Pangeanic Integrates OpenAI’s GPT-4 Model on Its NLP Platform to Provide Text Summaries and Ensure Data Privacy
BOSTON, March 17, 2023 (Newswire.com) - Leading Natural Language Processing (NLP) solutions company, Pangeanic, has announced the integration of OpenAI's GPT-4 model on its platform. This will allow users to access some of the features of the Generative Pre-trained Transformer (GPT) to summarize text, among other functions. In addition, customers will be able to combine it with Pangeanic's own anonymization and data masking solutions as a secure system so that no personal data is transferred from one jurisdiction to another.
With this integration, Pangeanic will enable users to use current and future releases of ChatGPT or other Large Language Models (LLM) with the tools and workflows of its NLP platform. The company's ECO platform is designed for the real needs of governments and businesses and helps institutions and corporations translate millions of documents with customized engines, mask data using full anonymization or pseudonymization techniques, classify information and extract knowledge from data.
Pangeanic's CEO, Manuel Herranz, highlights that the company focuses on AI techniques that deliver value and that its ECO platform is designed to provide full respect for privacy through the Masker data masking solution. Users can now benefit from not having to use prompts, and summarize documents through OpenAI's ChatGPT customization, as well as doing so securely, without revealing any personal details.
Pangeanic's mission is to combine the best of AI with human ingenuity, and its hybrid approach delivers the best results for NLP applications. AI does what it knows best, while humans remain the ultimate evaluators and decision-makers. The company is convinced that language is becoming a crucial use case for AI, and that this knowledge-based approach can reliably provide accurate results and ensure data privacy.
Contact Information:Marisol Letelier
Marketing Assistant
[email protected]
Original Source: Pangeanic Integrates OpenAI's GPT-4 Model on Its NLP Platform to Provide Text Summaries and Ensure Data Privacy
